NCT05451329View on ClinicalTrials.gov

A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure

PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

July 12, 2022

Primary Completion Date

December 22, 2022

Study Completion Date

December 22, 2022

Conditions
Glaucoma, Open-Angle
Interventions
DRUG

VVN539 Ophthalmic Solution 0.02%

Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days

DRUG

VVN539 Ophthalmic Solution 0.04%

Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days

DRUG

VVN539 Ophthalmic Solution Vehicle

Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days

Trial Locations (1)

27701

Lexitas, Durham

All Listed Sponsors
lead

VivaVision Biotech, Inc

INDUSTRY